What is the efficacy of the hyper-CVAD chemotherapy regimen followed by ASCT as a frontline treatment for mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Hyper-CVAD with or without rituximab followed by autologous stem cell transplantation (ASCT) was tested at the M.D. Anderson Cancer Center as a frontline regimen. It did not appear superior to hyper-CVAD over time, especially after the addition of rituximab to hyper-CVAD. [15]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!